Sponsor:
ECOG-ACRIN Cancer Research Group
Code:
NCT04566328
Conditions
Plasma Cell Myeloma
RISS Stage I Plasma Cell Myeloma
RISS Stage II Plasma Cell Myeloma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Bortezomib
Daratumumab and Hyaluronidase-fihj
Dexamethasone
Lenalidomide
Quality-of-Life Assessment
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-16. This information was provided to ClinicalTrials.gov by ECOG-ACRIN Cancer Research Group on 2024-08-09.